<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210872</url>
  </required_header>
  <id_info>
    <org_study_id>CGFL-QDV</org_study_id>
    <secondary_id>CDR0000683850</secondary_id>
    <secondary_id>CGFL-AFSSAPS-2008-A01468-47</secondary_id>
    <secondary_id>EU-21061</secondary_id>
    <nct_id>NCT01210872</nct_id>
  </id_info>
  <brief_title>Quality-Of-Life Assessment in Patients With Head and Neck Cancer Treated With Radiation Therapy</brief_title>
  <official_title>Impact of Quality of Life Assessment in Routine Oncology Practice for Head and Neck's Cancer Patients, Treated by Radiotherapy: Impact on the Satisfaction With Care, the Health Related Quality of Life and on the Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information over time about patients' quality-of-life and satisfaction
      with care may help doctors plan the best treatment and help patients live more comfortably.

      PURPOSE: This randomized clinical trial is studying quality-of-life assessment in patients
      with head and neck cancer treated with radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the impact of quality-of-life assessment in routine oncology practice on
           satisfaction with care, health-related quality-of-life, and toxicity in patients with
           primary nonmetastatic head and neck cancer treated with radiotherapy.

      Secondary

        -  To evaluate the feasibility of using quality-of-life tools in routine oncology practice.

        -  To evaluate the impact on the occurrence of toxicity.

        -  To determine the impact on overall survival.

        -  To study the concordance between the toxicity reported by the clinician and those
           reported by the patient quality-of-life questionnaires.

      OUTLINE: Patients are stratified according to sex, tumor localization, and TNM stage.
      Patients are randomized to 1 of 2 arms.

        -  Arm I: Patients complete quality-of-life questionnaires (EORTC tools only, including
           EORTC QLQ-SAT32, EORTC QLQ-C30, and specific module QLQ-H&amp;N35/Euroqol EQ-5D) before each
           consultation with the clinician for one year.

        -  Arm II: Patients undergo standard follow-up care comprising consultation with the
           clinician for one year.

      After completion of study, patients are followed up every 3 months for 1 year and then at 2
      years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Satisfaction of care (EORTC QLQ-SAT32)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life (EORTC QLQ-C30 and specific module QLQ-H&amp;N35/Euroqol EQ-5D)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (occurrence and length) according to NCI-CTC version 3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of primary nonmetastatic head and neck cancer

          -  No other primary cancer localizations

          -  No second tumor localization at the time of diagnosis

          -  Must be planning to be treated initially with radiotherapy

        PATIENT CHARACTERISTICS:

          -  No cognitive impairment or psychiatric history

          -  No history of other cancer

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Maingon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck Bonnetain, PhD</last_name>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>33-3-8073-7784</phone>
      <email>pmaingon@dijon.fnclcc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

